Tarsus Pharmaceuticals Inc (TARS)

NASD · Healthcare · Biotechnology · USA

Tarsus Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Tarsus Pharmaceuticals is a commercial stage biopharmaceutical company that markets XDEMVY, an ophthalmic solution for treating Demodex blepharitis caused by mite infestation. The company also develops product candidates for ocular rosacea and Lyme disease prevention.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Tarsus Pharmaceuticals Inc stock.

Our verdict on TARS

Overvalued: intrinsic value $59.80 per share, market price $78.20, margin of safety -30.8% (as of 2026-11-17).

A 4.2x revenue multiple, discounted for its losses, values the shares at $59.80; the price of $78.20 is 31% above that value.

ETFs with the most weight in TARS

17 more funds hold it; the full list is part of the paid plan.

More on TARS

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than TARS in Biotechnology

35 more in this industry show a wider margin of safety.

Is TARS undervalued or overvalued?

TARS is overvalued (as of the 2026-11-17 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $59.80; the price of $78.20 is 31% above that value.

What is the intrinsic value of TARS?

$59.80 per share (as of the 2026-11-17 close), against a market price of $78.20. That is a margin of safety of -30.8%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.